The aim of the present study, therefore, was to investigate whether cyclin A2 deficiency perturbs HR pathway in human breast cancer cells and to determine if its loss hypersensitizes the cells to DNA crosslinking agent, cisplatin, and PARP inhibitors, veliparib and olaparib. The gene discussed is CCNA2; the disease is breast carcinoma.